Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy

Neurotoxicity Clinical Trial

Official title:

Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04614987
• Other study ID #: 202009118
• Status: Terminated
• Start date: February 25, 2021
• Est. completion date: September 13, 2023

Study information

• Verified date: September 2023
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The investigators propose that immune effector cell-associated neurotoxicity syndrome (ICANS) is predicated upon the early loss of blood brain barrier (BBB) integrity with subsequent monocyte infiltration leading to cross-activation of native glial cells. Glial overstimulation leads to neuroinflammation, synaptic dysfunction, and ultimately neuronal injury.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 17
• Est. completion date: September 13, 2023
• Est. primary completion date: September 13, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Clinically scheduled to undergo treatment with tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, or lisocabtagene maraleucel.

• At least 18 years of age.

• Able and willing to undergo study testing (blood draws, lumbar punctures, neuro-psychiatric testing, and neuroimaging with MRI)

• Participants of childbearing potential without documented history of menopause or hysterectomy who choose to participate must not be pregnant at screening and must agree to avoid becoming pregnant prior to scanning.

• Able to understand and willing to sign an IRB-approved written informed consent document.

Exclusion Criteria:

• Has any condition that, in the Investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data (for example, participants unable to lie flat for the duration of the MRI scan).

• Contraindications to MR imaging (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate. Patients with pacemakers may only be scanned if approved by CCIR staff and radiology review.

• Severe claustrophobia.

• History of multiple sclerosis, Parkinson's disease, dementia (including Alzheimer's disease, frontotemporal dementia, and Pick's disease), or motor neuron disease including amyotrophic lateral sclerosis (ALS)

• For the lumbar puncture associated with the study only: contraindications to lumbar puncture (e.g. platelets <r 50,000/mm3, INR > 1.5, evidence of midline shift on imaging, presence of local infection at LP site, history of baclofen pump, history of significant spinal surgery/hardware which would preclude safe bedside lumbar puncture). If a contraindication to lumbar puncture develops while on study, patient may remain on study but will be barred from a lumbar puncture until that contraindication resolves.

• Pregnant

• Enrolled in an interventional study of a drug targeting neurotoxicity

Related Conditions & MeSH terms

• Brain Injuries
• Neurotoxicity

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (3)

Lead Sponsor	Collaborator
Washington University School of Medicine	McDonnell Center, Paula and Roger Riney Blood Cancer Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent changes in given biomarker levels	This includes serum (GFAP and NfL) and CSF biomarkers (NfL, VILIP-1, YKL-40, TREM2, and Neurogranin) measured using a single molecule array in pg/ml; Descriptive statistics will be used to summarize a given biomarker level at different time points.	From baseline to up to 180 days post-transfusion (estimated to be 7 months)
Secondary	Cross-sectional biomarker profiles	-Serum (GFAP, NfL) and CSF biomarkers (NfL, VILIP-1, YKL-40, TREM2, and Neurogranin) as measured using a single molecule array in pg/ml will be compared between participants who develop ICANS compared to participants who do not develop ICANS using descriptive statistics	From baseline to up to 180 days post-transfusion (estimated to be 7 months)
Secondary	Cross-sectional imaging profile	-Diffusion basis spectrum imaging (DBSI) separates the point diffusion properties of water by magnitude and direction to provide a non-invasive measurement of cellularity, extracellular edema, and axonal integrity/myelination in µm^2/msec. All three components will then be compared between participants who develop ICANS compared to participants who do not develop ICANS using descriptive statistics	From baseline to up to 180 days post-transfusion (estimated to be 7 months)
Secondary	Cytokine profiles	-Elisa-based assays will measure the CSF cytokine profile measurements of IL-2, IL-6, IL10, IFN-y, TNFa, GM-CSF (ng/ml), with descriptive statistics used to compare between participants who develop ICANS compared to participants who do not develop ICANS	From baseline to up to 180 days post-transfusion (estimated to be 7 months)
Secondary	Changes in cognitive assessment as measured by Symbol Digit Modalities Test (SDMT)	-The SDMT is a brief written test where participants use a key to match abstract symbols paired with numbers. The scale ranges from 0 to 110, with higher scores reflecting better function. By doing so, an indirect measure of attention, processing speed, motor speed, and visual scanning is obtained. Scores on formal testing will be then be analyzed in conjunction with quantification of imaging features (as parceled using DBSI) observed between participants who develop ICANS compared to participants who do not develop ICANs	Baseline, 30 days, 90 days, and 180 days post-transfusion (estimated to be 7 months)
Secondary	Changes in cognitive assessment as measured by Trail Making Test A/B	This brief written test has participants connect lines between sequential numbers and/or letters in a given pattern. By doing so, an indirect measure of executive function tests task switching, visual search, scanning, processing speed, and visual attention is obtained. Scores on formal testing will be then be analyzed in conjunction with quantification of imaging features (as parceled using DBSI) observed between participants who develop ICANS compared to participants who do not develop ICANs	Baseline, 30 days, 90 days, and 180 days post-transfusion (estimated to be 7 months)
Secondary	Changes in cognitive assessment as measured by Letter-Number Sequencing	-This brief cognitive test has participants listen to variable length strings of alphanumeric characters and repeat the characters back verbally in a specific order. They are then scored on the number of correct responses. Scores range from 0 to 21, with higher scores associated with improved cognitive function.; By doing so, a direct measure of working memory is obtained. Scores on formal testing will be then be analyzed in conjunction with quantification of imaging features (as parceled using DBSI) observed between participants who develop ICANS compared to participants who do not develop ICANs	Baseline, 30 days, 90 days, and 180 days post-transfusion (estimated to be 7 months)
Secondary	Changes in cognitive assessment as measured by Hopkins Verbal Learning Test-Received (HVLT-R3)	-This approximately 30 minute long cognitive test has participants learn and free-recall a collection of words from different categories. By doing so, a direct measure of recall and memory is obtained. Scores range from 0 to 30, with higher scores indicating improved cognitive function. Scores on formal testing will be then be analyzed in conjunction with quantification of imaging features (as parceled using DBSI) observed between participants who develop ICANS compared to participants who do not develop ICANs	Baseline, 30 days, 90 days, and 180 days post-transfusion (estimated to be 7 months)
Secondary	Changes in cognitive assessment as measured by Montreal-Cognitive Assessment (MocA)	-This approximately 15 minute long cognitive test consists of both written and verbal sections. Participants are scored on the number of correct answers out of 30 (i.e. scores range from 0-30), with higher scores reflecting improved cognitive performance. By doing so, an indirect measure surveying multiple cognitive domains is obtained. Scores on formal testing will be then be analyzed in conjunction with quantification of imaging features (as parceled using DBSI) observed between participants who develop ICANS compared to participants who do not develop ICANs	Baseline, 30 days, 90 days, and 180 days post-transfusion (estimated to be 7 months)

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine